Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00313521
Recruitment Status : Unknown
Verified December 2006 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : April 12, 2006
Last Update Posted : September 20, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well thiotepa works together with radiation therapy in treating young patients with newly diagnosed malignant brain tumors.

Condition or disease Intervention/treatment Phase
Brain and Central Nervous System Tumors Drug: thiotepa Procedure: adjuvant therapy Radiation: radiation therapy Phase 2

Detailed Description:



  • Determine tumor response to adjuvant thiotepa followed by radiotherapy in pediatric patients with newly diagnosed malignant astrocytic tumors.


  • Determine the acute and chronic toxicity of thiotepa in these patients.
  • Determine the variability in thiotepa metabolism by measuring plasma and cerebrospinal fluid pharmacokinetics of thiotepa and tepa in these patients.
  • Develop a phase II study framework model, to determine the chemosensitivity to new, single-agent regimens in the treatment of high-grade (malignant) astrocytic tumors, including anaplastic astrocytoma, glioblastoma, giant cell glioblastoma, and gliosarcoma.
  • Determine the incidence of distant neuraxial metastases in patients at the time of relapse.
  • Determine the 1-year disease-free survival rate in patients treated with this regimen.

OUTLINE: This is a multicenter study. Patients are stratified by age (3-15 vs 16-20 years of age).

  • Chemotherapy: Patients receive thiotepa IV continuously over 168 hours on days 1-7. Treatment repeats every 28 days for up to 2 courses. Patients then proceed to radiotherapy after blood counts recover.
  • Radiotherapy: Patients undergo external-beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.
  • Post-radiation chemotherapy: Patients with complete, partial, or objective response, or stable disease after 2 courses of thiotepa may receive thiotepa alone for up to 8 more courses at the discretion of the treating physician.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups
Study Start Date : June 1995
Estimated Primary Completion Date : November 1997

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Brain Tumors
Drug Information available for: Thiotepa

Primary Outcome Measures :
  1. Degree of surgical resection by surgical and radiological assessments

Secondary Outcome Measures :
  1. Tumor response to chemotherapy by imaging

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   3 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed diagnosis of 1 of the following high-grade (malignant) astrocytic tumors:

    • Anaplastic astrocytoma
    • Glioblastoma
    • Giant cell glioblastoma
    • Gliosarcoma
  • Any anatomical site except brain stem
  • Newly diagnosed disease
  • Has undergone tumor biopsy or surgical resection within the past 2 weeks

    • Patients with post-operative residual disease (grade III or IV) are eligible

      • Post-operative imaging of tumor within 72 hours of surgery
    • Patients with no imageable post-operative disease are not eligible
  • No neurological deterioration within 3 days of study treatment

    • Increasing requirement for steroids to control symptoms of intracranial pressure is considered evidence of neurological deterioration


  • Lansky play score 40-100%
  • Absolute neutrophil count > 1,000/mm^3
  • Platelet count > 100,000/mm^3
  • Creatinine ≥ 1.5 times upper limit of normal


  • See Disease Characteristics
  • No prior chemotherapy or radiotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00313521

Sponsors and Collaborators
Children's Cancer and Leukaemia Group
Layout table for investigator information
Study Chair: David A. Walker Queen's Medical Centre

Layout table for additonal information Identifier: NCT00313521    
Other Study ID Numbers: CDR0000454503
First Posted: April 12, 2006    Key Record Dates
Last Update Posted: September 20, 2013
Last Verified: December 2006
Keywords provided by National Cancer Institute (NCI):
untreated childhood cerebellar astrocytoma
childhood high-grade cerebral astrocytoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Nervous System Neoplasms
Central Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs